US-based Aclaris Therapeutics Inc. (NASDAQ: ACRS) and Shanghai firm Pediatrix Therapeutics Inc. entered into a license agreement, with Pediatrix taking on development, manufacturing, and commercial rights in Greater China to Aclaris’s ATI-1777. ATI-1777 is a Janus kinase (JAK) 1/3 inhibitor, while Pediatrix is granted rights for any indication including atopic dermatitis.
Deal Terms and Financials
The deal involves a USD 5 million upfront payment and up to USD 91 million in regulatory and sales-based milestone commitments, in addition to royalties on future sales to Aclaris. Pediatrix is focused on developing pediatric-friendly products for the China market, while the press release describes ATI-1777 as a ‘soft’ JAK inhibitor capable of use in treating a skin condition such as atopic dermatitis.-Fineline Info & Tech
